# PIVOT-10 (NCT03785925)

> A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03785925
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Nektar Therapeutics
- Conditions: Urinary Bladder Neoplasm; Neoplasm Metastasis
- Interventions: Bempegaldesleukin; Nivolumab
- Enrollment: 192
- Primary outcome: Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Per Blinded Independent Central Review (BICR) in Patients Whose Tumors Have Low Programmed Cell Death Ligand (PD-L1) Expression

## Commentary we found

- YouTube: 5
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=pivot-10-nct03785925